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ANALISIS MOLEKUL GEN SURVIVAL MOTOR NEURON (SMN) DAN 
NEURONAL APOPTOSIS INHIBITORY PROTEIN (NAIP) 
DALAM PESAKIT SPINAL MUSCULAR ATROPHY (SMA) DI MALAYSIA 
 
ABSTRAK 
 
Spinal Muscular Atrophy (SMA) adalah sejenis penyakit kelemahan saraf otot yang 
akhirnya menyebabkan kemerosotan otot. Penyakit ini disebabkan oleh mutasi 
pada gen Survival Motor Neuron 1 (SMN1). SMA diklasifikasikan kepada 3 
subjenis; jenis I, jenis II dan jenis III berdasarkan pada masa simptom kelemahan 
otot mula ditunjukkan dan juga tahap keterukan penyakit yang dialami. 
Kepelbagaian tahap keterukan penyakit di antara pesakit mungkin disebabkan oleh 
mutasi atau perubahan pada gen lain yang berkaitan seperti gen Survival Motor 
Neuron 2 (SMN2) dan/atau gen Neuronal Apoptosis Inhibitory Protein (NAIP). 
Objektif kajian ini adalah untuk menentukan frekuensi mutasi delesi gen SMN1 dan 
NAIP di kalangan pesakit SMA di Malaysia. Selain itu, hubungan antara bilangan 
salinan gen SMN2 dan tahap keterukan penyakit ini juga dikaji. Sejumlah 69 
sampel darah individu normal dan 69 sampel darah pesakit yang disyaki secara 
klinikal mengalami SMA, diperolehi dari hospital kerajaan dan juga institusi 
akademik di seluruh Malaysia. Delesi homozigus bagi gen SMN1 ditentukan 
melalui kaedah PCR diikuti oleh pemotongan menggunakan enzim restriksi. Bagi 
mengenalpasti delesi homozigus gen NAIP, asai PCR multiplex menggunakan gen 
β-globin sebagai kawalan dalaman telah dilakukan. Bagi sampel pesakit yang 
menunjukkan keputusan delesi homozigus SMN1 yang positif, sampel tersebut 
 xvi
digunakan untuk kajian seterusnya bagi menentukan bilangan salinan gen SMN2 
dengan menggunakan Real-time PCR. Sebanyak 81 peratus daripada pesakit 
yang secara klinikal disyaki menghidapi SMA telah menunjukkan keputusan positif 
delesi homozigus pada sekurang kurangnya exon 7 gen SMN1. Delesi homozigus 
NAIP dikenalpasti berlaku pada 9 daripada 42 pesakit yang positif delesi gen 
SMN1. Tujuh puluh lapan peratus daripada sampel tersebut adalah pesakit SMA 
jenis I. Analisis kuantifikasi pula menunjukkan bilangan salinan gen SMN2 yang 
tinggi didapati pada pesakit yang mempunyai fenotip yang tahap keterukan 
penyakit yang lebih rendah. Keputusan ini telah memberikan penunjuk penting 
bagi prognosis pesakit. Hasil kajian ini telah menunjukkan bahawa delesi gen 
SMN1 adalah penyebab utama bagi penyakit SMA di Malaysia. Kaedah 
pengambilan sampel darah yang tidak invasif berbanding kaedah konvensional ini 
sangat sesuai bagi tujuan diagnosa terutama bagi bayi yang baru dilahirkan. Delesi 
bagi gen NAIP lebih banyak didapati pada pesakit yang lebih teruk fenotipnya.    
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MOLECULAR ANALYSIS OF SURVIVAL MOTOR NEURON (SMN) 
AND NEURONAL APOPTOSIS INHIBITORY PROTEIN (NAIP)  
GENES IN SPINAL MUSCULAR ATROPY (SMA) PATIENTS IN MALAYSIA 
 
ABSTRACT 
 
Spinal Muscular Atrophy (SMA) is a neuromuscular disease which is clinically 
characterized by progressive muscular weakness and atrophy of the skeletal 
muscles. This degenerative disease is caused by mutation of the Survival Motor 
Neuron 1 (SMN1) gene. SMA is classified into 3 subtypes; type I, type II and type 
III based on age at onset and clinical severity. The variations of severity might be 
related with mutation or alteration in other associated genes such as Survival 
Motor Neuron 2 (SMN2) and/or Neuronal Apoptosis Inhibitory Protein (NAIP). The 
objectives of this study are to determine the deletion frequency of SMN1 and NAIP 
genes and study the relationship between the copies of SMN2 gene with severity in 
patients who have SMN1 gene deletion. A total of 69 normal blood samples and 69 
blood samples of clinically suspected SMA patients from various hospitals in 
Malaysia were recruited into this study. Homozygous deletion of the SMN1 gene 
was determined by PCR method followed by restriction enzyme digestion. NAIP 
gene deletion was determined by multiplex PCR assay whereby β-globin gene was 
used as an internal control. Samples found to have deletion of the SMN1 gene 
were then subjected to real-time PCR for the quantification of the SMN2 gene. 
Eighty-one percent of patients highly suspected to have SMA showed homozygous 
deletion of at least exon 7 of SMN1 gene. The NAIP gene deletion was detected in 
 xviii
9 out of 42 patients and 78% of them were patients with type I SMA. Quantification 
analysis showed a higher copy number of the SMN2 gene in patients with milder 
phenotype and could be an important indication for prognosis. From this study, 
deletion of the SMN1 gene was a major cause of SMA in these patients. This non-
invasive molecular genetic testing could be a useful tool for the diagnosis of SMA 
especially in newborn babies. NAIP gene deletion found in this study was mostly 
seen in severe type of SMA. 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
 
 
 
 
 
LITERATURE REVIEW 
 
 
 
 
1.1 The human body system 
 
 
The human body is made up of atoms, molecules, cells, tissues and organs. 
The organization of these organs is called system. The human body systems 
are the complex units that make up the body and are composed of 11 major 
systems including integumentary, nervous, skeletal, muscular, cardiovascular, 
endocrine, respiratory, digestive, reproductive, lymphatic, and urinary system. 
 
1.1.1 Nervous system 
 
The nervous system is the most complex of all human body systems. It is 
classified into two major divisions; the central nervous system (CNS) and 
peripheral nervous system (PNS). The central nervous system consists of the 
brain and spinal cord. The peripheral nervous system consists of all nervous 
tissues outside the brain and spinal cord (Figure 1.1). Functionally, the nervous 
system can be divided into the somatic nervous system which controls skeletal 
muscles, and autonomic nervous system (ANS) that controls smooth muscle, 
cardiac muscle and glands.  
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Brain 
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nervous  
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Figure 1.1: Brain and spinal cord build up central nervous system while 
peripheral nervous systems consist of peripheral nerves and 
sensory receptors 
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1.1.2 Development of central nervous system  
 
During embryogenesis, three germ layers, namely endoderm, mesoderm and 
ectoderm are formed (Table1.1). Endoderm gives rise to guts while the 
mesoderm to the rest of the organ. Ectoderm develops into skin and nervous 
systems. The development of nervous systems starts with the formation of the 
neural plate. In the third week of human development, neurulation occurs where 
the surface of ectoderms thickens and begins to sink and fold in on itself. By the 
end of this process, the neural tube is formed. Finally this neural tube forms the 
brain and spinal cord which constitutes the central nervous system.   
 
1.1.3 Neuronal development 
 
Neuron is the basic functional unit of the nervous system. Each neuron has two 
types of fibers extending from the cell body; dendrite and axon (Figure 1.2). The 
dendrite carries impulses toward the cell body while the axon carries impulses 
away from the cell body. Nerve cell bodies are derived from the neural tube or 
neural crest. This nerve cell processes the axons and dendrites which sprout 
from the cell bodies to the tissues and structures they innervate.  
 
Each neuron is part of a relay system that carries information through the 
nervous system. A neuron that transmits impulses toward CNS is a sensory 
neuron while a neuron that transmits impulses away from CNS is a motor 
neuron. There are connecting neurons within the CNS called synapses. At the 
synapse, energy is passed from one cell to another by means of a chemical 
neurotransmitter. 
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Table 1.1: Embryonic cells differentiate into a variety of different cell types 
 
Endoderm Mesoderm Ectoderm 
Lung cell (alveolar cell) 
Thyroid cell 
Pancreatic cell  
Cardiac muscle  
Skeletal muscle cell  
Tubule cell of kidney 
Red blood cells  
Smooth muscle (in gut)  
Skin cells of epidermis  
Neuron of brain  
Pigment cell 
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Dendrites 
Mitochondrion 
Nucleus 
Cell body 
Axon 
Node 
Schwann cell 
Muscle  
Myelin 
 
Figure 1.2: Neuron, the core components of brain, spinal cord and peripheral 
nerves 
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1.1.4 Spinal cord 
 
The spinal cord is the connection center for the reflexes as well as the afferent 
(sensory) and efferent (motor) pathways for most of the body below the head 
and neck. The spinal cord begins at the brainstem and ends at about the 
second lumbar vertebra. The spinal cord carries all the nerves to and from the 
limbs and lower part of the body. It is the pathway for impulses going to and 
from the brain. A cross-section of the spinal cord reveals an inner section of 
gray matter containing cell bodies and dendrites of peripheral nerves. The gray 
matter appears as a thickened and distorted letter ‘H’. The upper arms of the H 
are referred to as the dorsal horns (posterior horns) and the parts below are 
referred as the ventral horns (anterior horns). The outer region of white matter 
contains nerve fiber tracts and myelin sheath and conducts impulses to and 
from the brain.  
 
1.1.5 Transmission of signal  
 
The axons of ventral horn motor neurons exit via ventral roots. There are two 
types of motor neurons. Large alpha-motor neurons (skeletomotor neurons) 
innervate the ordinary skeletal muscle fibers, while gamma-motor neurons 
(fusimoto neurons) innervate the intrafusal muscle fibers of muscle spindles 
exclusively. The contractions of skeletal muscles are produced via the activation 
of the alpha-motor neurons. Damage or degeneration of the alpha-motor 
neurons causes failure of the impulse to be transferred to a motor unit and will 
finally affect the stretch reflex action (Figure 1.3).  
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Figure 1.3: The diagram showing a signal transmission (arrow) from the 
motor neuron to the muscle 
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1.2 Spinal Muscular Atrophy as a neurodegenerative disease 
 
Spinal Muscular Atrophy (SMA) is one of neuromuscular disorders. SMA was 
first described in the 1890s by Guido Werdnig of the University of Vienna and 
Johann Hoffmann of Heidelberg University (Markowitz et al., 2004). The term 
‘spinal’ was used because the main cause of the disease is degeneration of 
alpha-motor neuron, located in the anterior horn of the spinal cord. The 
disruption of the specific neuron causes failure of the impulse to be transferred 
from the brain to muscle for a response. The effect from transmission failure 
involves the muscular systems.  The muscles that do not function will eventually 
shrink or undergo wasting (atrophy). This condition mainly affects the proximal 
voluntary muscles or the muscles closest to the spinal cord, thus affecting 
activities such as crawling, swallowing, walking, and neck control, eventually 
leading to death.  
 
1.2.1 Classification and clinical description of SMA 
 
SMA is classified into 3 clinically subtypes; type I, type II and type III based on 
clinical features, age of onset and development of motor milestone (Munsat, 
1992). The diagnostic criteria for SMA were categorized and reported in the 
International SMA Consortium Meeting (26th -28th June 1992) in Bonn, 
Germany, published by European Neuro Muscular Center (ENMC). In 1998, the 
diagnostic criteria was revised and detailed in 59th ENMC International 
Workshop (Zerres and Davies, 1999) as shown in Appendix 1. The updating of 
the diagnostic criteria for SMA has been part of an agreement done by groups 
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of clinicians and researchers of neuromuscular disorders. Later, the diagnostic 
criteria becomes a guideline for clinicians to diagnose SMA. 
 
1.2.1 (a) Type I SMA  
 
Type I SMA is an acute type, also known as Werdnig-Hoffmann Disease. This is 
the most severe type of SMA. Majority of cases present before the age of 3 
months with lack of fetal movements in the final months of pregnancy and 
weakness at birth. The onset ranges from prenatal period to the age of 6 
months. Patients typically present with generalized muscle weakness, poor 
muscle tone and absence of tendon reflexes. They are hypotonic and never 
able to sit without support. Fasciculation of the tongue are seen in most but not 
all patients with type I. Normal reaction to sensory stimuli shows no sensory 
loss in patients. Mild contractures are often at knees and rarely seen at the 
elbows. The patients may also present with some ingestion, feeding and 
secretion problems as a result of the muscle weakness of respiratory and 
digestive systems. Almost all patients have a life expectancy of less than 2 
years. The mortality is typically due to respiratory failure or infection which is 
caused by weakness in the intercostal and accessory respiratory muscles. A 
typical clinical appearance of the patient is shown in Figure 1.4.  
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Figure 1.4: Clinical feature of type I SMA patient. The baby presents with 
hypotonia 
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1.2.1 (b) Type II SMA 
 
 
Type II SMA is the intermediate form with onset after 6 months of age, but less 
than 18 months. Patients with this type are able to sit independently but could 
not stand or walk. There is absence of tendon reflexes in about 70 percents of 
individuals (Iannaccone et al., 1993). Tongue fasciculation is one of the features 
that is present in type II. The life expectancy could be until adulthood and the 
intellectual skills of this group of patients are in the average range. Figure 1.5 
shows one of our patients with type II SMA.  
 
1.2.1 (c) Type III SMA 
 
 
Type III SMA is also known as Kugelberg-Welander Disease. It is the mildest 
form with the onset after the age of 18 months. Patients are able to stand and 
walk without aid. The lower limbs are usually more affected than the upper 
limbs. Affected limbs shows proximal muscle weakness. Patients with type III 
SMA usually have frequent falls or trouble walking up and down stairs at the 
age of two to three years. They have normal IQ and usually go to school and 
learn as other children. Figure 1.6 shows a child with SMA type III. 
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Figure 1.5: Type II SMA patient. Patient can sit but cannot stand or walk 
independently 
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Figure 1.6: Patient with type III SMA is able to stand without support 
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1.3 Genetics of SMA 
 
1.3.1 Genetic bases of different types of SMA     
 
SMA is an inherited disorder. This autosomal recessive disease is caused by 
mutation of Survival Motor Neuron (SMN) gene that encodes a multifunctional 
protein. SMN gene has been characterized as having a duplicated form; SMN1 
and SMN2 gene. This gene lies within a large region (about 20kb) containing 
several genes (Lefebvre et al., 1995). The presence of deletion (90%) and other 
intragenic mutations (10%) in the telomeric copies known as SMN1 gene in 
SMA patients confirmed that the SMN1 gene is responsible for this disease. 
There has been no reported cases of patients loosing both the SMN1 and 
SMN2 genes (Schwartz et al., 1997).  The neighboring genes such Survival 
Motor Neuron 2 (SMN2) and Neuronal Apoptosis Inhibitory Protein (NAIP) are 
thought to be the modifying genes as the disease varies from mild (type III) to 
very severe (type I) cases (Wirth et al., 1999, Harada et al., 2002).  
 
1.3.2 Inheritance of the disease 
 
SMA is an autosomal recessive disease which affects 1 in 10000 live births. 
The overall frequency for a carrier is 1 in 40 (Pearn, 1980). Mutation in either of 
the alleles causes an individual to be a carrier. If a carrier is married to another 
carrier, there will be a twenty five percent possibility of having a child with SMA. 
If both of the mutated allele are transfers from parents, the child will have this 
fatal disease. The child who received both of the normal alleles will be 
unaffected.  
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The possibility for a carrier parents to have an unaffected child with carrier 
status is 50 percent. When one of the mutated allele is transferred from either 
mother or father, the child will be a carrier. The explanation of this mode of 
inheritance is described in Figure 1.7.   
 
1.3.3 The discovery of SMA candidate genes 
 
All three types of SMA; severe, intermediate and mild, have been reported to be 
due to different mutations at a single locus on the long arm of chromosome 5 
(Melki, 1990). Brzustowicz et al., (1990) later mapped the candidate gene at a 
specific region of 5q12.2-13.3 by linkage analysis.  
 
In the beginning, the severity of this disease was associated with Ag1-CA 
alleles which are complex marker (DiDonato et al., 1994). This marker is a short 
tandem repeat of nucleotide CA which is also known as microsatellite. The Ag1-
CA alleles are located in each of the promoter region of SMN gene. The 
numbers of repeats differed in each of the promoter region for each allele. 
Usually, normal individuals have 2 copies of SMN1 gene and 2 copies of SMN2 
gene. Thus, the amplification of Ag1-CA in a normal individual shows 4 different 
sizes of the marker. DiDonato et al., (1994) found patients with type I SMA 
predominantly produce a single AFLV allele whereas majority of type II patients 
amplified an allele with two or three amplification fragment length variants 
(AFLVs). They suggested that this marker clearly identifies the critical region 
that should be searched for SMA candidate genes. 
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Figure 1.7: The possibility of a carrier parents to transfer the genetic 
information to the offspring. Blue color indicates a normal allele 
while the white color indicates a mutated allele 
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In 1995, Lefebvre et al characterized the SMA-determining gene and found the 
evidence of a large inverted duplication of an element of approximately 500kb, 
termed ETel for the telomeric and ECen for the centromeric elements. The ETel 
(SMN1, Survival Motor Neuron 1) and ECen (SMN2, Survival Motor Neuron 2) 
were later successfully distinguished by southern blotting analysis (Roy et al., 
1995b). Survival Motor Neuron (SMN) gene was later found to be the 
responsible gene for this disease (Lefebvre et al., 1995) while Neuronal 
Apoptosis Inhibitory Protein (NAIP) gene was reported to be deleted in most of 
the patients with severe type (Roy et al., 1995a) .  
 
1.3.3 (a) Survival Motor Neuron gene 
 
The SMN gene spans about 20kb with 9 exons (Burglen et al., 1996). SMN 
gene is characterized by an inverted duplication which exists in two highly 
homologous copies known as SMN1 and SMN2 gene. Analysis of the genomic 
sequence of these genes revealed 5 nucleotide differences between SMN1 and 
SMN2. The differences are one nucleotide in intron 6, one in exon 7, two in 
intron 7, and one in exon 8 respectively (Figure 1.8). 
 
All the 5 differences between SMN1 and SMN2 did not result in any change in 
the amino acid coded. Both of the genes expressed the same peptide sequence 
for the SMN protein. However, the alteration in the nucleotide sequence (C to T) 
in exon 7 of SMN2 causes splicing of this exon 7 during the transcriptional 
process. This results in the formation of truncated SMN2 protein (Lorson et al., 
1999). Exon 7 of SMN1 gene encodes a protein with a last terminal-C 16 
residues while the transcript of SMN2 gene is lacking of this vital protein which  
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causes the produced protein to be not self-oligomerized (Hofmann et al., 2000) 
and unstable both in vivo and in vitro.  
 
The SMN gene encodes a 294 amino acid with 38kDa of SMN protein. The 
SMN protein is ubiquitously expressed and localized in both nucleus and 
cytoplasm (Coovert et al., 1997).  
 
In nucleoplasm, SMN protein is found in a concentrated form in subnuclear 
structure known as Gems. Gems is also known as ‘Gemini of Cajal bodies’ 
because of the similarities in number and size with Cajal bodies (Liu and 
Dreyfuss, 1996). The ultrasructural study showed Gems represent a distinct 
category of nuclear body (Navascues et al., 2004). This subnuclear structure 
also gives the same response to metabolic condition as Cajal bodies (CBs). 
CBs is a nuclear accessory bodies described as a roughly spherical, typically 
0.1-1.0µm in size (Lamond and Carmo-Fonseca, 1993) and exist in about 1-5 
per nucleus. This structure is mainly derived from metabolically active cells such 
as neuron or cells that are highly propagated like cancer cells (Matera, 2003).  
 
The difference between CBs and Gems is the presence of small nuclear 
ribonucleoprotein (snRNPs) in the CBs. snRNPs is a complex of snRNA protein 
which consist of four different snRNP (U1, U2, U4/U6, and U5), essential 
mediators of RNA processing events.  Two proteins were identified by Liu and 
Dreyfuss in 1996 that are essential in the biogenesis and recycling of snRNPs 
which are SMN and its associated protein, SIP1. This SMN-SIP1 protein 
complex associate with snRNPs and formed a complex of multiprotein (Fischer 
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et al., 1997) called spliceosomal snRNPs which is involved in pre-mRNA 
splicing.   
 
The SMN protein was shown to interact with itself before associating with other 
protein (Liu and Dreyfuss, 1996). Full-length SMN protein produced by SMN1 is 
needed for the self-oligomerization before the interaction with other protein to 
form a large complex of multiprotein.  
 
The expression of SMN protein is normally very high in the spinal cord of 
normal individuals and was shown to be reduced by 100-fold in samples of type 
I SMA. In type I SMA fibroblast, the number of gems is greatly reduced 
compared to type II, type III, carrier and normal individual (Coovert et al., 1997).  
 
To date, there are enough findings to prove that deletion of SMN1 gene being 
the major cause for the SMA disease. However, the mechanism on how 
deficiency of SMN protein causes a specific defect in degeneration of motor 
neuron is still unclear.  
 
1.3.3 (b) Neuronal Apoptosis Inhibitory Protein gene 
 
The Neuronal Apoptosis Inhibitory Protein (NAIP) gene is a part of 500kb 
inverted duplication on chromosome 5q13. It lies adjacent to the SMN1 gene 
and close to each other with the ends probably less than 20kb apart. NAIP gene 
contains at least 16 exons and encodes for 1232 amino acids of 140kDa protein 
(Roy et al., 1995a).  
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The protein sequence encoded by NAIP gene exons 6-12 contains a region 
which is homology to baculovirus protein (Birnbaum et al., 1994). This protein 
was found to inhibit cell apoptosis in insects induced by virus (Clem and Miller, 
1993). Expression of NAIP in mammalian cells was also shown to inhibit 
apoptosis induced by a variety of signals (Liston et al., 1996).  
 
The NAIP was identified as one of the SMA-related gene after it was found to 
be deleted in the most severe type of SMA patients. The RT-PCR amplification 
of RNA from SMA and non-SMA tissue revealed that at least some of the 
internally deleted and truncated NAIP versions are transcribed in SMA patients. 
Based on the data obtained, deletion of NAIP gene was suggested to be 
consistent with defects in SMA either resulting in or contributing to the SMA 
phenotype (Roy et al., 1995a). However, until today the role of NAIP in SMA 
has not been fully clarified. 
 
1.4 Diagnosis of SMA 
 
Common diagnostic methods for SMA include observing the degeneration of 
cells from muscle biopsy, electromyography (EMG) and/or Nerve Conduction 
Studies (NCS). 
 
1.4.1 Muscle Biopsy 
 
Muscle biopsy is performed to examine small muscle tissues, usually taken 
from the thigh. The tissue is stained and observed under microscope to 
investigate the degeneration of muscle fibers. Typically, muscle biopsy shows 
 22
degeneration of muscle fibers without inflammation, fibrosis or histochemical 
abnormality. Patients with severe weakness have many small fibers which show 
features of denervation. However, the set back of this procedure is it is invasive 
and sometimes may give inconclusive results especially in newborn babies.  
 
 
1.4.2 Electromyography (EMG) and Nerve Conduction Study (NCS) 
 
EMG is a procedure used to assess motor units in various portions of the body 
such as cells located in the anterior horn, brain stem, axons, and the muscle 
fibers they innervate via neuromuscular junctions. An electrical current that 
passes across the nerve membrane shows up as an electrical activity on the 
EMG monitor.  This procedure is done to exclude the abnormalities of the 
peripheral neuromuscular system. However, EMG could not be used as a 
screening procedure for neuromuscular disease because there are too many 
nerves and muscles that can be assessed by this procedure. Nerve conduction 
study is done to record the motor and sensory amplitude. In SMA patients, 
sensory amplitude is usually normal while the motor amplitude is decreased.      
 
1.4.3 Molecular genetic testing  
 
The Polymerase Chain Reaction-Restriction Enzyme (PCR-RE) method 
established in 1995 by van der Steege et al. has become the most accurate and 
non-invasive method of diagnosis of SMA compared to muscle biopsy and 
EMG. A small amount of blood from patient is needed to extract the DNA. This 
method is simple and suitable to be applied for diagnostic testing.  
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In 2001, allele-specific PCR was studied as a simple method compared with 
PCR-RE method (Moutou et al., 2001). This method took a shorter time but 
needs more evaluation to be applied for genetic diagnosis because of the 
unique features of this gene. The highly homologous copy of the SMN1 and 
SMN2 genes causes a possibility of mismatch to occur and may result in false-
positive.  
 
Another technique of molecular genetic screening and diagnosis is by using 
denaturing high performance liquid chromatography (dHPLC). This technique 
has proven to be rapid, accurate and sensitive for the genetic and prenatal 
diagnosis of SMA (Zhu et al., 2006). However, the cost for the maintenance of 
the equipment may not be affordable by each hospital or government institute.  
This equipment is normally available at the referral center and the application of 
dHPLC for the services of routine screening may not be suitable to be applied in 
each government hospital.  
 
1.5 Prenatal diagnosis of SMA 
 
The knowledge of genetic information and methods of molecular diagnosis has 
made it possible for prenatal diagnosis of SMA to be carried out. The source of 
genetic material is usually the chorionic villus sample.  
 
A more non-invasive procedure has been studied using the circulating fetal cells 
in maternal blood (Beroud et al., 2003) and fetal normoblasts in maternal blood 
(Chan et al., 1998). This method is based on separation of fetal cells from 
maternal cells depending on the size of the cells. Epithelial cells which originate 
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from the fetus are easily found in maternal blood. The cells are usually larger 
than red blood cells and other cells and could be separated in accordance with 
size. After obtaining the fetal DNA sources, the molecular analysis for detecting 
homozygous deletion can be done by the PCR-RE approach or other molecular 
methods.   
 
1.6 Therapeutic trials in SMA 
 
Since SMA phenotype is proportional to the amount of full-length protein 
produced, most of the attempts in therapeutic trials are targeted towards 
elevating the full-length SMN protein. Aclarubicin is a compound which is able 
to restore SMN2 splicing pattern in vitro by promoting exon 7 inclusions. 
However, the side effects and toxicity of this compound makes it unsuitable for 
the treatment of young SMA patients (Andreassi et al., 2001).  
 
The mouse model on mutant mice carrying the homozygous mutation of SMN1 
exon 7 has been studied to determine the neuroprotective activity by riluzole. 
However, no significant improvements were shown to improve the loss of 
proximal axons. Furthermore, severe side effects of riluzole in young animals 
also raised concerns on the potential toxicity in infants (Haddad et al., 2003). 
 
Histone deacetylase (HDAC) inhibitors are also being studied for the therapy of 
SMA. HDAC inhibitor has been used for the treatment of cancer and 
neurodegenerative diseases. Valproic acid (VPA), an HDAC inhibitor was tested 
on fibroblast cultures derived from SMA patients. This well-known drug was 
able to increase the SMN protein levels by restoring the correct splicing of the 
